Tag: Philips
From data to diagnosis
August 21, 2026Dan Leonard
An estimated 1 billion people worldwide are living with obstructive sleep apnea (OSA), yet approximately 85% remain undiagnosed. This matters because undiagnosed OSA can significantly impact patients’ quality of life and increase the risk of other conditions like hypertension, heart disease and stroke. While these figures are staggering, innovations in consumer wearables are creating an opportunity to bridge this gap – not as a replacement for medical-grade diagnosis, but as a catalyst...
New agreement allows Exor to increase stake in Philips
August 11, 2026HME News Staff
AMSTERDAM – Philips and Exor have agreed to update their long-term relationship agreement. It provides Exor with the flexibility to increase its shareholding in Philips to up to 22% of the company’s issued ordinary share capital and voting rights, up from the previous 20% cap, with the possibility of increasing its stake further subject to approval by the Philips Supervisory Board. Governance arrangements remain unchanged, including Exor's right to nominate one member of the Philips...
Philips sees growth in Connected Care despite shift in order timing
July 29, 2026Liz Beaulieu, Editor
AMSTERDAM – Philips reported a low double-digit increase in sales for Sleep and Respiratory Care during the second quarter of 2026, helping drive gains within its Connected Care business unit.
That’s compared to a 4% increase in sales company wide and a 2% increase for all of Connected Care.
Philips expects order growth to rebound
Philips reported a 1% decline in order intake for the second quarter – partly due to certain large orders in Patient Monitoring, also part of...
Philips reports benefit from US tariff refund
July 28, 2026HME News Staff
AMSTERDAM – Philips has reported group sales of EUR 4.4 billion for the second quarter of 2026, a 4% comparable increase. Income from operations were EUR 609 million, including a U.S. tariff refund benefit of EUR 186 million.
Other financial results:
Adjusted EBITA margin increased to 16.4%, including U.S. tariff refund benefit of effectively 4.2%
Operating cash flow of EUR 376 million, with free cash flow of EUR 222 million, including receipt of U.S. tariff refund
“We...
Philips continues to lean on international sleep growth, as FDA path continues
May 8, 2026Liz Beaulieu, Editor
AMSTERDAM – The Sleep and Respiratory Care (SRC) business at Philips grew in the low single digits in the first quarter of 2026, but its obstructive sleep apnea (OSA) portfolio stood out with double-digit growth outside of the U.S., says CEO Roy Jakobs.
International markets fuel OSA growth
OSA growth was particularly strong in Japan, the company’s second-largest market, Jakobs said during a recent conference call to discuss the company’s financial results.
“If you...
Philips delivers ‘good start to 2026,’ CEO says
May 6, 2026HME News Staff
AMSTERDAM – Philips reported group sales of EUR 3.9 billion for the first quarter of 2026, a 4% increase compared to the same period last year. Sales for Connected Care, which includes the Sleep and Respiratory Care segment, increased 3%.
Other financial results:
Comparable order intake growth 6%
Income from operations increased to EUR 241 million
Adjusted EBITA margin increased 40 basis points to 9.0%
Operating cash flow of EUR 188 million, with free cash flow of EUR 28 million
“We...
In brief: Coral ‘getting started,’ Access Infusion expanding, Medline piloting automation
April 22, 2026HME News Staff
NEW YORK – Coral, a health care automation platform built for durable medical equipment (DME) and other specialty providers, has announced a $12.5 million investment led by Lightspeed and Z47 to grow its team and enhance its products.
The platform connects to existing EHR systems, fax lines and payer portals and automates end-to-end administrative workflows.
“Every person in the health care system is being slowed down by the same thing: administrative work that was never built to...
Philips issues correction for Trilogy Evo Platform ventilators
April 20, 2026HME News Staff
AMSTERDAN – Philips has issued a correction for Trilogy Evo Platform Ventilators, according to the U.S. Food and Drug Administration (FDA). The company has identified issues related to the use of prohibited non-pneumatic nebulizers and the obstruction alarm timing. As of March 6, it has reported three serious injuries and no deaths associated with these issues. Philips has sent affected customers a letter recommending that they:
Update all Trilogy Evo Platform ventilators with software...
In brief: AAH’s call to action, DreamStation’s new designation, CMS’s new ABN
March 20, 2026HME News Staff
WASHINGTON – AAHomecare is urging providers to build support for the DIABETES Act (S. 4037), which, among other things, would delay Medicare competitive bidding for continuous glucose monitors (CGMs) and insulin pumps for five years.
The bill, which was introduced March 12 by Sens. Jeanne Shaheen, D-N.H., and Susan Collins, R-Maine, would also expand Medicare coverage of diabetes self-management training sessions.
AAHomecare says stakeholders can build important early support for this...
Philips DreamStation receives medically necessary designation for certain patients
March 19, 2026HME News Staff
ANDOVER, Mass. – Philips has announced that DreamStation BiPAP AVAPS devices have been designated as medical necessary for lower-weight patients with breathing impairment. The devices, which include S, T, S/T, and PC modes with AVAPS, are available for sale in the United States for new setups for patients with obstructive sleep apnea (OSA) and respiratory impairment, who are both >7 years of age and weighing 40-66 pounds. “Patient safety is at the...